Therapeutic Prostate Cancer Vaccine Candidate Launches Initial Study
Oslo-based Ultimovacs ASA announced on February 18, 2021, the first patient's treatment in the Phase I TENDU trial, representing the start of clinical evaluation for the Company's Tetanus-Epitope Targeting (TET)-platform.
The TET platform allows for the production of multiple therapeutic cancer vaccines that can strengthen and increase T cell responses to cancer cells by targeting antigens that are specific to one type of cancer or common to many tumor types.
By combining cancer antigens and the vaccine adjuvant in the same molecule, this unique platform can generate vaccine candidates with a beneficial safety and administration profile, presenting an opportunity to treat patients at an early stage of their disease.
The TENDU clinical trial, conducted at the Oslo University Hospital, is a first-in-human, dose-escalation study designed to generate initial safety and immune activation data for a prostate cancer-specific therapeutic TET-based vaccine in relapsed prostate cancer patients.
Ultimovacs seeks to become a leader in developing immune-stimulatory vaccines to treat a broad range of cancers. Ultimovacs' lead universal cancer vaccine candidate UV1 leverages the high prevalence of the human telomerase to be effective across the dynamic stages of the tumor's growth and its microenvironment. The Company expects to provide the first interim, preliminary safety readout from the trial by the end of 2021.